RT Journal Article
T1 Management of hepatitis B virus infection after liver transplantation.
A1 Jiménez-Pérez, Miguel
A1 González-Grande, Rocío
A1 Mostazo Torres, José
A1 González Arjona, Carolina
A1 Rando-Muñoz, Francisco Javier
K1 Hepatitis B virus
K1 Liver transplantation
K1 Recurrence
K1 Prophylaxis
K1 Hepatitis B immunoglobulin
K1 Humanos
K1 Inmunoglobulinas
K1 Cirrosis hepática
K1 Neoplasias hepáticas
K1 Trasplante de hígado
K1 Pronóstico
K1 Tenofovir
K1 Antivíricos
K1 Carcinoma hepatocelular
K1 Hepatopatía terminal
K1 Anticuerpos de la hepatitis
K1 Hepatitis B crónica
AB Chronic hepatitis B virus (HBV) infection is responsible for up to 30% of cases of liver cirrhosis and up to 53% of cases of hepatocellular carcinoma. Liver transplantation (LT) is the best therapeutic option for patients with end-stage liver failure caused by HBV. The success of transplantation, though, depends on receiving prophylactic treatment against post-transplant viral reactivation. In the absence of prophylaxis, liver transplantation due to chronic hepatitis B (CHB) is associated with high rates of viral recurrence and poor survival. The introduction of treatment with hepatitis B immunoglobulins (HBIG) during the 1990s and later the incorporation of oral antiviral drugs have improved the prognosis of these patients. Thus, LT for CHB is now a universally accepted option, with an estimated 5 years survival of around 85% vs the 45% survival seen prior to the introduction of HBIG. The combination of lamivudine plus HBIG has for many years been the most widely used prophylactic regimen. However, with the appearance of new more potent oral antiviral agents associated with less resistance (e.g., entecavir and tenofovir) for the treatment of CHB, new prophylactic strategies are being designed, either in combination with HBIG or alone as a monotherapy. These advances have allowed for more personalized prophylaxis based on the individual risk profile of a given patient. In addition, the small pool of donors has required the use of anti-HBc-positive donors (with the resulting possibility of transmitting HBV from these organs), which has been made possible by suitable prophylactic regimens.
PB Baishideng Publishing Group Inc
SN 1007-9327
YR 2015
FD 2015-11-14
LK http://hdl.handle.net/10668/2195
UL http://hdl.handle.net/10668/2195
LA en
NO Jiménez-Pérez M, González-Grande R, Mostazo Torres J, González Arjona C, Rando-Muñoz FJ. Management of hepatitis B virus infection after liver transplantation. World J. Gastroenterol. 2015; 21(42):12083-90
NO Journal Article; Review;
DS RISalud
RD Apr 8, 2025